NRAS and colorectal carcinoma: In CRC, 4.2% (38 of 907) of hotspot alterations associated with on-label matched therapies, which included BRAF V600E, KRAS G12C, other KRAS alterations (contraindicated), and NRAS alterations (contraindicated), were detected at a VAF <5%.